Relationship between humoral response against hepatitis C virus and disease overcome

SpringerPlus

Volumn 3, Issue 1, 2014, Pages 1-12

  Brakha, Carine ^a,f   Arvers, Philippe ^b   Villiers, Florent ^c   Marlu, Alice ^d   Buhot, Arnaud ^e   Livache, Thierry ^e   Calemczuk, Roberto ^e   Zarski, Jean Pierre ^d   Villiers, Christian L ^a,f   Marche, Patrice N ^a,f   Villiers, Marie Bernadette ^a,f  

^a INSTITUT ALBERT BONNIOT   (France)

^b HIA Desgenettes   (France)

^c Bldg 142   (United States)

^d Centre Hospitalier Universitairede Grenoble   (France)

^e CEA GRENOBLE   (France)

^f UNIV GRENOBLE ALPES   (France)

Author keywords

Antibody; Epitope; Hepatitis C virus; Peptide chip; SPR imaging

Indexed keywords

EID: 84897762536     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-56     Document Type: Article

References (42)

1. Araujo AC, Astrakhantseva IV, Fields HA, Kamili S (2011) Distinguishing acute from chronic hepatitis C virus (HCV) infection based on antibody reactivities to specific HCV structural and nonstructural proteins. J Clin Microbiol 49(1):54-57.
2. Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, Nevins JR, Ali-Osman F, Tyler DS (2009) Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 15(2):502-510.
3. Bassett SE, Brasky KM, Lanford RE (1998) Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J Virol 72(4):2589-2599.
4. Brillanti S, Masci C, Ricci P, Miglioli M, Barbara L (1992) Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C. Hepatology 15(6):998-1001.
5. Chen Z, Weck KE (2002) Hepatitis C virus genotyping: interrogation of the 5′ untranslated region cannot accurately distinguish genotypes 1a and 1b. J Clin Microbiol 40(9):3127-3134.
6. Chen M, Sallberg M, Sonnerborg A, Weiland O, Mattsson L, Jin L, Birkett A, Peterson D, Milich DR (1999) Limited humoral immunity in hepatitis C virus infection. Gastroenterology 116(1):135-143.
7. Chen J, Liu H, Yang J, Chou KC (2007) Prediction of linear B-cell epitopes using amino acid pair antigenicity scale. Amino Acids 33(3):423-428.
8. Cherif B, Roget A, Villiers CL, Calemczuk R, Leroy V, Marche PN, Livache T, Villiers MB (2006) Clinically related protein-peptide interactions monitored in real time on novel peptide chips by surface plasmon resonance imaging. Clin Chem 52(2):255-262.
9. Desombere I, Van Vlierberghe H, Weiland O, Hultgren C, Sallberg M, Quiroga J, Carreno V, Leroux-Roels G (2007) Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C. J Med Virol 79(6):701-713.
10. El Awady MK, El Abd YS, Shoeb HA, Tabll AA, Hosny Ael D, El Shenawy RM, Atef K, Bader El Din NG, Bahgat MM (2006) Circulating viral core and E1 antigen levels as supplemental markers for HCV chronic hepatitis. Virol J 3:67.
11. Gabrielli A, Zhang ZX, Cherubini G, Candela M, Savoldi S, Manzin A, Clementi M, Amoroso A, Sallberg M (1996) Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia. Clin Exp Immunol 105(1):59-64.
12. Gane EJ, Maertens G, Ducatteeuw A, Qian KP, Lau JY, Jones H, Davies E, Naoumov NV, Williams R (1999) Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation. Transplantation 67(1):78-84.
13. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M (2012) Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci USA 109(16):6205-6210. doi:10.1073/pnas.1114927109.
14. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439):531-537.
15. Gremion C, Cerny A (2005) Hepatitis C virus and the immune system: a concise review. Rev Med Virol 15(4):235-268.
16. Gutierrez JA, Klepper AL, Garber J, Walewski JL, Bateman K, Khaitova V, Syder A, Tscherne DM, Gauthier A, Jefferson D, Rice CM, Schiano TD, Branch AD (2011) Cross-genotypic polyclonal anti-HCV antibodies from human ascitic fluid. J Virol Methods 171(1):169-175.
17. Hilfenhaus J, Krupka U, Nowak T, Cummins LB, Fuchs K, Roggendorf M (1992) Follow-up of hepatitis C virus infection in chimpanzees: determination of viraemia and specific humoral immune response. J Gen Virol 73(Pt 4):1015-1019.
18. Hope RG, McLauchlan J (2000) Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein. J Gen Virol 81(Pt 8):1913-1925.
19. Hwang SJ, Tong MJ, Lai PP, Ko ES, Co RL, Chien D, Kuo G (1996) Evaluation of hepatitis B and C viral markers: clinical significance in asian and caucasian patients with hepatocellular carcinoma in the United states of America. J Gastroenterol Hepatol 11(10):949-954.
20. Irshad M, Khushboo I, Singh S, Singh S (2008) Hepatitis C virus (HCV): a review of immunological aspects. Int Rev Immunol 27(6):497-517.
21. Klein KC, Dellos SR, Lingappa JR (2005) Identification of residues in the hepatitis C virus core protein that are critical for capsid assembly in a cell-free system. J Virol 79(11):6814-6826.
22. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nature medicine 14(1):25-27.
23. Lohr HF, Elste C, Dienes HP, Michel G, Braun HB, Meyer zum Buschenfelde KH, Gerken G (1996) The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha. J Hepatol 25(3):292-300.
24. Maksimov P, Zerweck J, Maksimov A, Hotop A, Gross U, Pleyer U, Spekker K, Daubener W, Werdermann S, Niederstrasser O, Petri E, Mertens M, Ulrich RG, Conraths FJ, Schares G (2012) Peptide microarray analysis of in silicopredicted epitopes for serological diagnosis of Toxoplasma gondii infection in humans. Clin Vaccine Immunol 19(6):865-874.
25. Nasoff MS, Zebedee SL, Inchauspe G, Prince AM (1991) Identification of an immunodominant epitope within the capsid protein of hepatitis C virus. Proc Natl Acad Sci USA 88(12):5462-5466.
26. Nikolaeva LI, Blokhina NP, Tsurikova NN, Voronkova NV, Miminoshvili MI, Braginsky DM, Yastrebova ON, Booynitskaya OB, Isaeva OV, Michailov MI, Archakov AI (2002) Virus-specific antibody titres in different phases of hepatitis C virus infection. J Viral Hepat 9(6):429-437.
27. Novotny J, Handschumacher M, Haber E, Bruccoleri RE, Carlson WB, Fanning DW, Smith JA, Rose GD (1986) Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains). Proc Natl Acad Sci USA 83(2):226-230.
28. Perez-Gordo M, Lin J, Bardina L, Pastor-Vargas C, Cases B, Vivanco F, Cuesta-Herranz J, Sampson HA (2012) Epitope mapping of Atlantic salmon major allergen by peptide microarray immunoassay. Int Arch Allergy Immunol 157(1):31-40.
29. Sallberg M, Ruden U, Wahren B, Magnius LO (1992) Immunodominant regions within the hepatitis C virus core and putative matrix proteins. J Clin Microbiol 30(8):1989-1994.
30. Sallberg M, Ruden U, Wahren B, Magnius LO (1993) Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site with the envelope 1 protein. Clin Exp Immunol 91(3):489-494.
31. Sillanpaa M, Melen K, Porkka P, Fagerlund R, Nevalainen K, Lappalainen M, Julkunen I (2009) Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection. Virol J 6:84.
32. Sollner J (2006) Selection and combination of machine learning classifiers for prediction of linear B-cell epitopes on proteins. J Mol Recognit 19(3):209-214.
33. Sturn A, Quackenbush J, Trajanoski Z (2002) Genesis: cluster analysis of microarray data. Bioinformatics 18(1):207-208.
34. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Bernards R, Friend SH (2003) Expression profiling predicts outcome in breast cancer. Breast Cancer Res 5(1):57-58.
35. Villiers M-B, Cortes S, Brakha C, Marche P, Roget A, Livache T (2009) Polypyrrolepeptide microarray for biomolecular interaction analysis by SPR imaging. Methods Mol Biol 570:317-328.
36. Villiers MB, Cortes S, Brakha C, Lavergne JP, Marquette CA, Deny P, Livache T, Marche PN (2010) Peptide-protein microarrays and surface plasmon resonance detection: biosensors for versatile biomolecular interaction analysis. Biosens Bioelectron 26(4):1554-1559.
37. Villiers M-B, Brakha C, Buhot A, Marquette C, Marche PN (2011) Stability of peptide microarrays: a challenge for high-throughput screening. In: Schab-Balcerzak E (ed) Electropolymerization. InTech, Rijeka, Croatia, pp 199-214.
38. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Ohkawa K, Fusamoto H, Kamada T (1994) Hepatitis C virus replication and antibody responses toward specific hepatitis C virus proteins. Hepatology 19(6):1360-1365.
39. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Mita E, Ohkawa K, Katayama K, Fusamoto H, Kamada T (1996) Quantitative analysis of antibody to hepatitis C virus envelope 2 glycoprotein in patients with chronic hepatitis C virus infection. Hepatology 23(5):947-952.
40. Zein NN (2003) The epidemiology and natural history of hepatitis C virus infection. Cleve Clin J Med 70(4):S2-S6.
41. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD (2006) Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 3(1):e13.
42. Zibert A, Kraas W, Ross RS, Meisel H, Lechner S, Jung G, Roggendorf M (1999) Immunodominant B-cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection. J Hepatol 30(2):177-184.